Qilu Pharmaceutical's Novel GalNAc-Conjugated siRNA Drug QLS7320 Receives IND Approval for Paroxysmal Nocturnal Hemoglobinuria

On April 22, Qilu Pharmaceutical announced that its self-developed Class 1 innovative drug QLS7320 Injection had received clinical trial implied permission from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, and will soon be launched in China.ForParoxysmal Nocturnal Hemoglobinuria (PNH)Clinical research.QLS7320 Injection is a complement-targeted siRNA drug that achieves liver-targeted delivery through conjugation with GalNAc (N-acetylgalactosamine).

PNH is a rare acquired hemolytic disease driven by abnormal activation of the complement system, characterized by intravascular hemolysis, thrombotic events, and bone marrow failure, which can be life-threatening. Some patients respond poorly to existing treatments. Targeting the complement pathway is considered one of the fundamental strategies for treating these diseases. Qilu PharmaceuticalThe press release stated,QLS7320 is a complement-targeted drug with a novel mechanism of action., which is expected to bring new treatment options for patients.

References:
[1]Qilu Pharmaceutical's Small Nucleic Acid Drug Platform Achieves Breakthrough as QLS7320 Injection Receives Clinical Approval. From https://mp.weixin.qq.com/s/U3Ia47sDtFglCxeu2hBN5Q

Disclaimer: This article is for the purpose of information exchange only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.